Abstract
Purpose. To obtain new cardiovascular agents with mixed Ca2+-channel antagonistic and NO-donor properties, a series of “hybrid” 1,4-dihydropyridines (1,4-DHPs), bearing NO-donating furoxan moieties on the 3-positioned lateral ester chain were synthesized and pharmacologically characterized. Furazan analogues were also prepared and investigated for control purposes, because they are unable to release NO.4
Methods. Synthesis of the models was achieved by a modified Hantzsch approach. All of the final furoxan 1,4-DHPs were assessed for their ability to produce nitrite in the presence of a large excess of cysteine by the Griess reaction. Vasodilating activity was evaluated on rat aorta and expressed as EC50 and EC50 MB values, obtained in the absence and in the presence of methylene blue (MB) respectively, a well-known guanylate cyclase inhibitor. Affinities to 1,4-DHP receptor on Ca2+-channels, expressed as IC50 values, were determined through displacement experiments of [3H]-nitrendipine on rat cortex homogenates.
Results. Some hybrid compounds (derivatives 15a, 15b, 16a, and 16b) displayed vasodilating activity depending predominantly on their Ca2+-channel blocker properties. By contrast, some others (derivatives 17a, 17b, and 21) behaved as well-balanced hybrids with mixed Ca2+-channel blocking and NO-dependent vasodilating activities.
Conclusion. This work demonstrates the possibility of obtaining well-balanced hybrids endowed with mixed NO-donor and Ca2+-channel blocker properties using appropriate 1,4-DHP and furoxan moieties. A procedure for the individual evaluation of the NO-dependent vasodilator component and that due to Ca2+-channel blocking is proposed.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
REFERENCES
S. S. Baldwin. Drug design. In M. Williams and S. B. Malick (eds.), Drug Discovery Development, Humana Press, Clifton, NJ, 1987.
J. A. M. Christiaans and H. Timmerman. Cardiovascular hybrid drugs: Combination of more than one pharmacological property in one single molecule. Eur. J. Pharm. Sci. 4:1-22 (1996) and references therein.
R. Fruttero, D. Boschi, A. Di Stilo, and A. Gasco. The furoxan system as a useful tool for balancing “hybrids” with mixed α1-antagonist and NO-like vasodilator activities. J. Med. Chem. 38:4944-4949 (1995).
D. Boschi, A. Di Stilo, C. Cena, M. Lolli, R. Fruttero, and A. Gasco. Studies on agents with mixed NO-dependent vasodilating and β-blocking activities. Pharm. Res. 14:1750-1757 (1997).
A. Di Stilo, S. Visentin, C. Cena, A. M. Gasco, G. Ermondi, and A. Gasco. New 1,4-dihydropyridines conjugated to furoxanyl moieties, endowed with both nitric oxide-like and calcium channel antagonist vasodilator activities. J. Med. Chem. 41:5393-5401 (1998).
M. Bertinaria, G. Sorba, C. Medana, C. Cena, M. Adami, and G. Morini. Synthesis and pharmacological characterisation of new H2-antagonists containing NO-donor moieties endowed with mixed antisecretory and gastroselective activities. Helv. Chim. Acta 83:287-299 (2000).
Y. Kawashima, T. Kato, A. Nakazato, K. Tsuchida, K. Hatayama, S. Hirono, and I. Moriguchi. Structure-activity study of antihypertensive 1,4-dihydropyridine derivatives having nitrooxyalkyl moieties at the 3 and 5 positions. Chem. Pharm. Bull. 41:1060-1065 (1993) and references therein.
N. Iqbal and E. E. Knaus. Synthesis and smooth muscle calcium channel antagonist effects of dialkyl 1,4-dihydro-2,6-dimethyl-4-aryl-3,5-pyridinedicarboxylates containing a nitrooxy or nitrophenyl moiety in the 3-alkyl ester substituent. Arch. Pharm. Med. Chem. 329:23-26 (1996) and references therein.
H. Bohn, J. Brendel, P. A. Martorana, and K. Schönafinger. Cardiovascular actions of the furoxan CAS 1609, a novel nitric oxide donor. Br. J. Pharmacol. 114:1605-1612 (1995).
M. Hecker, W. Vorhoff, A. T. Bara, P.I. Mordvintcev, and R. Busse. Characterization of furoxans as a new class of tolerance-resistant nitrovasodilators. Naunyn-Schmiedeberg's Arch. Pharmacol. 351:426-432 (1995).
A. M. Gasco, D. Boschi, and A. Gasco. Unsymmetrically substituted furoxans. Part 15. Bromination of dimethylfuroxan related compounds with NBS. J. Heterocyclic Chem. 32:811-813 (1995).
G. Sorba, G. Ermondi, R. Fruttero, U. Galli, and A. Gasco. Unsymmetrically substituted furoxans. Part 16. Reaction of benzenesulfonyl substituted furoxans with ethanol and ethanethiol in basic medium. J. Heterocyclic Chem. 33:327-334 (1996).
G. Sorba, C. Medana, R. Fruttero, C. Cena, A. Di Stilo, U. Galli, and A. Gasco. Water soluble furoxan derivatives as NO prodrugs. J. Med. Chem. 40:2288, 463-469 (1997).
M. Feelisch. In M. Feelisch and J. S. Stamler (eds.), Methods in Nitric Oxide Research, John Wiley, Chichester, 1996.
C. Medana, G. Ermondi, R. Fruttero, A. Di Stilo, C. Ferretti, and A. Gasco. Furoxans as nitric oxide donors. 4-Phenyl-3-furoxancarbonitrile: Thiol-mediated NO release and biological evaluation. J. Med. Chem. 37:4412-4416 (1994).
J. M. Fukuto, K. Chiang, R. Hszieh, P. Wong, and G. Chadhuri. The pharmacological activity of nitroxyl: A potent vasodilator with activity similar to nitric oxide and/or endothelium-derived factor. J. Pharmacol. Exp. Ther. 263:546-551 (1992).
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Cena, C., Visentin, S., Di Stilo, A. et al. Studies on Agents with Mixed NO-Dependent and Calcium Channel Antagonistic Vasodilating Activities. Pharm Res 18, 157–165 (2001). https://doi.org/10.1023/A:1011072116210
Issue Date:
DOI: https://doi.org/10.1023/A:1011072116210